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Abstract: Porcine placenta extract (P-placenta) is widely applied in medicine and cosmetics. However, few
studies have examined the effect of the extract on the cellular behavior of the osteoblastic cell line Saos-2.
Here, we demonstrated that P-placenta enhances the proliferation, collagen type I production, and alkaline
phosphatase (ALP) secretion of Saos-2 in vitro. Proliferation of Saos-2 was assessed by MTT and DNA synthesis
assays. Type I collagen production and ALP secretion were evaluated using enzyme-linked immunosorbent
assay and ALP assays. The cells were treated with/without 20, 200 and 2000 g/ml of P-placenta for 24 h. We
found that 200 g/ml P-placenta significantly induced the proliferation of Saos-2 and enhanced type I collagen
production and ALP secretion. The results indicate that P-placenta controls the cellular behavior of osteoblasts,
resulting in the secretion of early bone-related biomarkers.
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Introduction
The placenta is a temporary organ that supports fetal growth
by supplying oxygen and nutrients1). The organ stores diverse
molecules such as vitamins, bioactive peptides, minerals, and
growth factors2,3). The placental extract has attracted attention
worldwide owing to its potential as drugs for clinical treatments4)
and as supplements in cosmetics3,4). Previous studies showed that
placental extract has various therapeutic effects, such as wound-
healing5), anti-inflammatory6), and immune-modulating potential7).
More recently, we reported that porcine placenta extract (P-
placenta) controls type I collagen production, cell proliferation,
and anti-inflammatory cytokine production of human gingival
fibroblasts (HGFs)8). However, its pharmaceutical mechanism in
other cells, such as bone-related cells, has not been thoroughly
examined.
Bone metabolism is systematically regulated by the complex
iteration of bone formation and resorption. Osteoblasts mainly
engage in bone formation by secreting extracellular matrix, such
as type I collagen and other organic proteins. Alkaline phosphatase
(ALP) secreted from osteoblasts degrades inorganic pyrophosphate
to phosphate, which is associated with the mineralization of bone9).
Therefore, type I collagen and ALP are important indicators of
bone metabolism10,11). However, little information is available
regarding the effect of placenta on the cellular metabolism of
osteoblasts.
The aim of this study was to evaluate the effect of P-placenta
on osteoblastic cells, particularly cell proliferation, type I collagen
production, and ALP secretion. To evaluate these issues, we used
the osteoblastic cell line Saos-2, which was first established from
osteosarcoma in 198712). ALP secretion, type I collagen production,
and mineralized matrix production have been evaluated in Saos-
2 cells and osteoblasts12). These cells present mature osteoblastic
characteristics13), and thus have been extensively investigated in
oncology14) and bone biology studies13). Additionally, biomaterial
function was previously evaluated using Saos-2 cells15,16).
Materials and Methods
Reagents
P-placenta was purchased from Nippon Meat Packers, Inc.
(Osaka, Japan). The powder-like extract was composed of natural
components from the porcine placenta without any additives.
Therefore, we used these reagents for the following experiments.
Cell maintenance
Saos-2 cells (HTB85) were provided by the Riken BRC Cell
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Bank (Tsukuba, Japan). Cells were cultured in Dulbecco’s
Modified Eagle Medium (DMEM, Nissui Pharmaceutical Co.,
Ltd., Tokyo, Japan) containing 10% fetal bovine serum (FBS) at
5% CO2 and 37°C.
3-(4, 5-Dimethylthial-2-yl)-2, 5-diphenyltetrazolium bromide
(MTT) and DNA synthesis assay
For DNA synthesis, Saos-2 seeded at 3.1 x 104/cm2 were
cultured in DMEM containing 0.5% FBS with/without P-placenta
at doses of 20, 200, and 2000 g/ml for 24 h. The level of DNA
synthesis in cells was determined by measuring BrdU-
incorporation using the Frontier BrdU Cell Proliferation assay kit
(Millipore, Billerica, MA, USA). For the MTT assay, cells were
cultured in DMEM containing 10% FBS with P-placenta at the
above concentrations for 24 h. The MTT assay was conducted as
reported previously17).
Type I collagen production
Cells were seeded at the 3.1 x 104/cm2 in DMEM with 10%
FBS, followed by treatment with DMEM containing 1% FBS with/
without P-placenta (200 g/ml) for 24 h. The levels of collagen
type I in the media were measured by an enzyme-linked
immunosorbent assay (ELISA), using a biotinylated anti-collagen
type I antibody (0.2 mg/ml, Rockland Immunochemicals,
Limerick, PA, USA). Total protein levels were quantified in the
cell lysate isolated with 0.5% Triton X-100 by using a BCA protein
assay kit (Thermo Fisher Scientific, Waltham, MA, USA).
Collagen production was normalized to the protein content in the
cell lysates.
ALP assay
Cells were seeded at a density of 3.1 x 104/cm2 in DMEM
containing 10% FBS. Next, the cells were treated with DMEM
containing 1% FBS with/without P-placenta (200 g/ml) for 24
h. The cells were lysed with 0.05% TritonX-100 (200 l), followed
by centrifugation at 14,000 xg for 1 min, and the supernatants
were collected. ALP activity in the lysates (20 l) was measured
using a LabAssay ALP kit (Wako Pure Chemicals Industries, Ltd.,
Osaka, Japan). Protein levels in the cell lysates were also measured
using the BCA protein assay kit (Thermo Fisher Scientific). ALP
activity was normalized to the total protein level in the cell lysates.
Statistical analysis
Statistical analysis was carried out using StatMate software
(ATMS, Tokyo, Japan). Statistical significance was evaluated by
one-way analysis of variance with a Dunnett’s test or by student’s
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Figure 1. Effect of P-placenta on the proliferation of Saos-2 cells.
(a) DNA synthesis assay. (b) MTT assay. Saos-2 seeded at a volume
of 3.1 × 104/cm2 were exposed to media containing 20, 200, or
2000 µg/ml P-placenta (designated as +, ++, and +++) for 24 h.
All data were compared with those for cells treated with control
medium without P-placenta (none). Data are shown as the mean ±
standard deviation (n = 3). *P < 0.05, **P < 0.01 and ***P <
0.001, analyzed with analysis of variance with a Dunnett’s test
(vs. none).
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Figure 2. Type  I collagen production
in Saos-2 cells treated with P-
placenta. Saos-2 cells were seeded
at a volume of 3.1 × 104/cm2 and
exposed to media containing 200 µg/
ml P-placenta for 24 h. Data are
shown as the mean ± standard
deviation (n = 3). **P < 0.01,
analyzed by Student’s t-test (vs.
none).
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Figure 3. ALP secretion in Saos-2
cells treated with P-placenta. Saos-
2 cells were seeded at 3.1 × 104/cm2,
and exposed to media containing
200 µg/ml P-placenta for 24 h. Data
are shown as the mean ± standard
deviation (n = 3). **P < 0.01,
analyzed by Student’s t-test (vs.
none)
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t-test. Levels of P < 0.05, P < 0.01 and P < 0.001 were considered
to indicate statistical significance.
Results
Effect of P-placenta on Saos-2 cell proliferation
After 24 h of treatment, 200 g/ml P-placenta increased the
level of DNA synthesis compared to the effect of other
concentrations in Saos-2, whereas no obvious change was
observed at 2000 g/ml P-placenta treatment (Fig.1a). The MTT
assay showed that 200 g/ml P-placenta significantly elevated
the cell viability of Saos-2 cells (Fig.1b). These results suggest
that there is optimal concentration of P-placenta that facilitates
Saos-2 cell proliferation.
Effect of P-placenta on type I collagen production and ALP
secretion from Saos-2 cells
Based on the proliferation assay results, we further evaluated
the effect of the P-placenta on type I collagen production and
ALP secretion from Saos-2 cells. Addition of P-placenta to the
media significantly increased the levels of type I collagen
production (Fig. 2) and ALP secretion (Fig. 3) from Saos-2 cells
compared to that in media without P-placenta.
Discussion
Although P-placenta may have therapeutic potential not only
in medicinal drugs but also in cosmetic supplements3), its detailed
function in the cellular metabolism of osteoblasts remains unclear.
In the present study, we demonstrated P-placenta enhances the
cell proliferation and regulates the synthesis and secretion of bone-
related proteins in osteoblastic Saos-2 cells.
Under the P-placenta stimulation, 200 g/ml condition
significantly enhanced  the proliferation of Saos-2 in vitro. In
contrast, 2000 g/ml P-placenta showed a negligible effect on
cell proliferation (Fig. 1). We previously reported that HGFs shows
a similar cell proliferation tendency under the same P-placenta
concentration8). Yoshikawa et al. reported that 0–100 g/ml P-
placenta elevated the proliferation of human skin fibroblasts18).
These results suggest that concentrations near 100 and 200 g/ml
are sufficient for inducing the proliferation of human somatic cells
originating from mesenchymal stem cells by using P-placenta in
vitro.
Using 200 g/ml P-placenta, we found that the extract induced
type I collagen production and ALP secretion from Saos-2 cells
in vitro. The mechanism by which P-placenta elevated this
secretion remains unclear. However, P-placenta is produced from
porcine placenta extract without any impurities. P-placenta and
human placenta extract4,19) are known to contain various minerals,
vitamins and growth factors. Including insulin-like growth factor-
1, a key regulator of fetal development, are synthesized in
placenta20). Type I collagen synthesis in Saos-2 cells is reportedly
upregulated by insulin-like growth factor-110). Moreover, Saos-2
cells respond to  extracellular  calcium21),  hormones12),
microRNAs22), and growth factors10). These results support that
the multiple molecules in P-placenta synergistically, rather than
solely, promote type I collagen production and ALP secretion.
A study conducted in Italy indicated that placenta treatment
improved periodontal disease, a major cause of tooth loss23).
However, few studies have evaluated how placenta extract controls
the condition of inflammation and bone loss in periodontal disease.
More recently, we reported that P-placenta has an anti-
inflammatory effect on HGFs in vitro8). The current study indicates
that P-placenta can elevate the secretion of bone-related protein
(type I collagen and ALP), which are pivotal in bone formation
(Figs. 2 and 3). Although there is a wide gap between in vitro and
in vivo results, additional studies may reveal the mechanism
underlying these effects of placenta on bone formation via protein
production of osteoblastic cells, which may be useful for treating
periodontal diseases. Peri-implant diseases lead to implant failure
due to bone loss and loss of osseointegration24). Therefore,
preventing or treating these diseases is important in dental implant
treatment. Regeneration therapy has been advocated as an approach
for curing peri-implant diseases25). Given the function of P-placenta
in in vitro culture of Saos-2 cells in the present study, this extract
might be effective for the treatment of not only periodontitis, but
also peri-implant diseases, and in bone regenerative therapy.
However, because the present study was performed under limited
conditions and cell lines, additional studies of primary osteoblasts
are imperative. Further detailed in vivo experiments are also
required to support these results.
In conclusion, we demonstrated that P-placenta enhanced the
cell proliferation, type I collagen production, and ALP secretion
of Saos-2 cells in vitro. Although it remains unknown how placenta
extract modulates the secretion of other bone-related proteins, our
results suggest that the extract modulates the cellular functions of
osteoblastic cells.
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